![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » FDA WARNS LILLY FOR ALIMTA MARKETING
FDA WARNS LILLY FOR ALIMTA MARKETING
Federal regulators asked pharmaceutical maker Eli Lilly and Co. to withdraw a "misleading" marketing brochure for its cancer drug Alimta. The Food and Drug Administration said the Indianapolis-based company published a
34-page patient brochure that "omits material facts and risk information
essential to the safe and effective use" of the 2-year-old drug.
The
News-Sentinel
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct